At the ASCO 2019 congress, the annual meeting of the American Society of Clinical Oncology, I had the opportunity to connect in various meetings and discussions with the Oncology Community.

When patients become our experts

We are used to hearing about cancer treatments in relation to a specific part of the body such as the breast, lung or prostate. But recently, there has been a paradigm shift in how we approach cancer treatment.

For patients with some types of cancer, genomic testing can change their treatment course. The results of such tests can help doctors match some patients to specific treatments that could benefit them.

The United States Food and Drug Administration (U.S. FDA) has approved a new treatment option for children and adults suffering from TRK fusion cancer.

Life expectancy is increasing and there is an acceleration of global population aging. The global health community must take action to proactively address age-related diseases.

New advances have improved our knowledge of the inner workings of cells, and once again we are witnessing a paradigm shift in how we could treat cancer in the future.

The evolution of immuno-oncology (IO) represents a major advancement in cancer therapy over the past decade. Across all different tumors around 70 percent of patients who receive IO treatments do not benefit from them.